KOPS - Das Institutionelle Repositorium der Universität Konstanz

Comparison of neuroprotective effects of erythropoietin (EPO) and carbamylerythropoietin (CEPO) against ischemia-like oxygen-glucose deprivation (OGD) and NMDA excitotoxicity in mouse hippocampal slice cultures

Comparison of neuroprotective effects of erythropoietin (EPO) and carbamylerythropoietin (CEPO) against ischemia-like oxygen-glucose deprivation (OGD) and NMDA excitotoxicity in mouse hippocampal slice cultures

Zitieren

Dateien zu dieser Ressource

Prüfsumme: MD5:b024bb609dbe33d44b66cda5b6a17319

MONTERO, Maria, Frantz Rom POULSEN, Jens NORABERG, Agnete KIRKEBY, Johan VAN BEEK, Marcel LEIST, Jens ZIMMER, 2007. Comparison of neuroprotective effects of erythropoietin (EPO) and carbamylerythropoietin (CEPO) against ischemia-like oxygen-glucose deprivation (OGD) and NMDA excitotoxicity in mouse hippocampal slice cultures. In: Experimental Neurology. 204(1), pp. 106-117. ISSN 0014-4886. eISSN 1090-2430. Available under: doi: 10.1016/j.expneurol.2006.09.026

@article{Montero2007-03Compa-40764, title={Comparison of neuroprotective effects of erythropoietin (EPO) and carbamylerythropoietin (CEPO) against ischemia-like oxygen-glucose deprivation (OGD) and NMDA excitotoxicity in mouse hippocampal slice cultures}, year={2007}, doi={10.1016/j.expneurol.2006.09.026}, number={1}, volume={204}, issn={0014-4886}, journal={Experimental Neurology}, pages={106--117}, author={Montero, Maria and Poulsen, Frantz Rom and Noraberg, Jens and Kirkeby, Agnete and van Beek, Johan and Leist, Marcel and Zimmer, Jens} }

<rdf:RDF xmlns:dcterms="http://purl.org/dc/terms/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:bibo="http://purl.org/ontology/bibo/" xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:void="http://rdfs.org/ns/void#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > <rdf:Description rdf:about="https://kops.uni-konstanz.de/rdf/resource/123456789/40764"> <dc:creator>Noraberg, Jens</dc:creator> <bibo:uri rdf:resource="https://kops.uni-konstanz.de/handle/123456789/40764"/> <foaf:homepage rdf:resource="http://localhost:8080/jspui"/> <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2017-11-28T15:16:45Z</dc:date> <dc:creator>Leist, Marcel</dc:creator> <dcterms:hasPart rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/40764/1/Montero_2--bztvtene74ys6.pdf"/> <dc:contributor>Noraberg, Jens</dc:contributor> <dcterms:issued>2007-03</dcterms:issued> <dc:creator>Montero, Maria</dc:creator> <dc:creator>Kirkeby, Agnete</dc:creator> <dc:contributor>Zimmer, Jens</dc:contributor> <dc:creator>van Beek, Johan</dc:creator> <dcterms:title>Comparison of neuroprotective effects of erythropoietin (EPO) and carbamylerythropoietin (CEPO) against ischemia-like oxygen-glucose deprivation (OGD) and NMDA excitotoxicity in mouse hippocampal slice cultures</dcterms:title> <dc:creator>Poulsen, Frantz Rom</dc:creator> <dc:contributor>Kirkeby, Agnete</dc:contributor> <dspace:hasBitstream rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/40764/1/Montero_2--bztvtene74ys6.pdf"/> <dc:contributor>van Beek, Johan</dc:contributor> <dc:contributor>Montero, Maria</dc:contributor> <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/> <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2017-11-28T15:16:45Z</dcterms:available> <dc:contributor>Poulsen, Frantz Rom</dc:contributor> <dc:contributor>Leist, Marcel</dc:contributor> <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/rdf/resource/123456789/28"/> <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/rdf/resource/123456789/28"/> <dc:creator>Zimmer, Jens</dc:creator> <dc:language>eng</dc:language> <dcterms:abstract xml:lang="eng">In addition to its well-known hematopoietic effects, erythropoietin (EPO) also has neuroprotective properties. However, hematopoietic side effects are unwanted for neuroprotection, underlining the need for EPO-like compounds with selective neuroprotective actions. One such compound, devoid of hematopoietic bioactivity, is the chemically modified, EPO-derivative carbamylerythropoietin (CEPO). For comparison of the neuroprotective effects of CEPO and EPO, we subjected organotypic hippocampal slice cultures to oxygen-glucose deprivation (OGD) or N-methyl-d-aspartate (NMDA) excitotoxicity. Hippocampal slice cultures were pretreated for 24 h with 100 IU/ml EPO (=26 nM) or 26 nM CEPO before OGD or NMDA lesioning. Exposure to EPO and CEPO continued during OGD and for the next 24 h until histology, as well as during the 24 h exposure to NMDA. Neuronal cell death was quantified by cellular uptake of propidium iodide (PI), recorded before the start of OGD and NMDA exposure and 24 h after. In cultures exposed to OGD or NMDA, CEPO reduced PI uptake by 49+/-3 or 35+/-8%, respectively, compared to lesion-only controls. EPO reduced PI uptake by 33+/-5 and 15+/-8%, respectively, in the OGD and NMDA exposed cultures. To elucidate a possible mechanism involved in EPO and CEPO neuroprotection against OGD, the integrity of alpha-II-spectrin cytoskeletal protein was studied. Both EPO and CEPO significantly reduced formation of spectrin cleavage products in the OGD model. We conclude that CEPO is at least as efficient neuroprotectant as EPO when excitotoxicity is modeled in mouse hippocampal slice cultures.</dcterms:abstract> </rdf:Description> </rdf:RDF>

Dateiabrufe seit 28.11.2017 (Informationen über die Zugriffsstatistik)

Montero_2--bztvtene74ys6.pdf 76

Das Dokument erscheint in:

KOPS Suche


Stöbern

Mein Benutzerkonto